2017-04-13 13:16:50 UTC

Liver & Biliary Sessions Scheduled at DDW® 2017

April 17, 2017

Council leadership hand-picked a preview of sessions for you to add to your DDW® itinerary.

The Liver and Biliary (L&B) section is focused on providing state-of-the-art programming in all aspects of clinical, translational and basic science research as it relates to liver disease and transplantation, and is bringing this knowledge to several abstract-driven sessions at Digestive Disease Week (DDW) 2017.

Check out the recommended sessions below. You can also use the AGA Institute Council Highlights at DDW 2017 booklet to view all section programming, committee sponsored and joint society sessions, as well as a plethora of basic science and clinical practitioner offerings. Not registered for DDW yet? There is still time — secure your spot and join your L&B colleagues in Chicago.

Session Title: AGA Emmet B. Keeffe Symposium — Prevention of Viral Hepatitis Through Vaccination: Done or Just Getting Started?
Session Date: Monday, May 8, 2017
Session Time: 4 p.m.
Why You Should Attend: Vaccine preventable disease issues remain problematic for many clinicians. Not all people who should be vaccinated are, some vaccines are not recommended for all at risk, and responses to vaccines vary. In some cases, (HCV and HEV) vaccines are either not available at all, or not available on a global basis for all at risk persons. This symposium will explore key issues in vaccination for viral agents that cause hepatitis.

Session Title: HIV and Liver Disease
Session Date: Monday, May 8, 2017
Session Time: 8 a.m.
Why You Should Attend: Gastroenterologists are often faced with the referral of HIV-infected persons, where liver disease processes are often multifactoral and require more complex management than in non-HIV infected patients. This symposium this review epidemiology and mechanisms of disease, as well as current treatment paradigms for the HBV and HCV patient with HIV.

Session Title: The Dr. Charles S. Lieber Lecture — Mechanisms of Liver Injury in NAFLD and NASH
Session Date: Sunday, May 7, 2017
Session Time: 2 p.m.
Why You Should Attend: NAFLD/NASH is an emerging epidemic in western countries. Despite known associations of NAFLD/NASH with obesity and metabolic syndrome, the underlying mechanisms of this important disease state and the differential spectrum of phenotypic disease presentation remain unclear. This lecture features an international expert who will provide up-to-date information regarding that status of NAFLD/NASH research.

More on Hepatitis (other)

Building Foundations Among Payers & Providers for Collaborative Care in HCV & HIV

Dec. 7, 2017

In this video, leading experts in HCV, HIV, and managed care engage in a crossfire panel discussion on key challenges, considerations and solutions for improving patient management, and appropriate access to HCV and HIV therapies.

Risk Factors of Prednisolone May Outweigh Benefit in Treatment of Severe Alcoholic Hepatitis (SAH)

Aug. 17, 2017

Gastroenterology researchers discuss their findings in video abstract.

Previously Cured HCV Patients Can Be Reinfected

Aug. 3, 2017

Prevention will require attention to high-risk behaviors.